New drug LNF1901 for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new experimental drug called LNF1901 for people with advanced cancers that have not responded to or cannot tolerate standard treatments. It aims to see if the drug is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have an advanced cancer that standard treatments didn't help or you couldn't tolerate
- You are able to get around and take care of yourself (ECOG score 0-1)
- Your blood counts and organ functions (liver, kidney, thyroid, clotting) are within a certain range
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests NBL-020, an injected medicine, in adults with advanced solid cancers (and possibly some skin T-cell lymphoma) to see how it works and how safe it is. You may be considered if standard treatment has stopped working or isn’t tolerated and if you can provide recent tumor tissue for lab testing.
This trial tests a new drug called LNF2105 in people with advanced solid tumors that have not responded to other treatments. The drug targets a protein called Nectin-4 found on many cancer cells, and researchers want to see if LNF2105 can help shrink or control these tumors.
This trial tests a new drug called LNF2007 for people with advanced solid tumors like stomach, pancreatic, or bile duct cancer. It's for those who have tried standard treatments without success. The study aims to see if LNF2007 is safe and effective.
This trial tests a new drug called NV-001 for people with advanced solid tumors that are no longer responding to standard treatments. It aims to see if the drug is safe and can help shrink or slow tumor growth.
This is an early-stage study testing a new drug called JL19001, alone or combined with standard treatments, for people with advanced solid tumors (like melanoma, lung cancer, or kidney cancer) or relapsed/refractory B-cell lymphoma who have exhausted standard options. The trial aims to find the safest dose and understand how well the drug works.
This early-phase trial tests NB002, a new immune-targeting medicine, to find safe doses and see how well it can treat advanced or metastatic solid cancers that have not responded to standard treatments. It may help by strengthening the immune system’s ability to fight the tumor.
Hear when a new Advanced Malignant Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.